Angle Edges Closer To US FDA Clearance For Liquid Biopsy System
Executive Summary
Angle is moving closer to becoming the first company to receive US FDA-clearance for a system that captures and harvests intact circulating tumor cells from patient blood for analysis.
You may also be interested in...
Angle Targets March For US FDA De Novo Submission
Following a Q-submission meeting with the US FDA, liquid biopsy firm Angle says it is in a strong position to progress a de novo submission for the Parsortix system by end of Q1.
Abbott Strikes Deal With British Liquid Biopsy Company Angle
Abbott and UK-based Angle plc announced they will collaborate on a breast cancer liquid biopsy study, assessing Angle's technology for harvesting circulating tumor cells in combination with Abbott's FDA-approved gene-based test for determining HER-2 status.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.